Stephanie Fierros
Medical · Dallas, TXNPI 1366010605
Payments from drug & device makers
Across 130 payments — averaging $22.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$512
- AstraZeneca$502
- Astellas Pharma US Inc$348
- Lilly USA, LLC$306
- Boehringer Ingelheim$283
- GSK$238
- plus $729 from 14 others
What the payments were for
- Food & beverage$2,72593%
- Education$1937%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 21 | $512 |
| AstraZeneca | 18 | $502 |
| Astellas Pharma US Inc | 12 | $348 |
| Lilly USA, LLC | 15 | $306 |
| Boehringer Ingelheim | 13 | $283 |
| GSK | 10 | $238 |
| Exact Sciences | 7 | $157 |
| Pfizer | 5 | $109 |
| AbbVie | 4 | $84 |
| Phathom Pharmaceuticals, Inc. | 5 | $74 |
| Avvisto Therapeutics, LLC | 3 | $51 |
| Novartis | 3 | $44 |
| Dexcom, Inc. | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $36 |
| Bayer | 2 | $32 |
| Edwards Lifesciences | 1 | $29 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Phadia US Inc. | 1 | $14 |
| Genentech USA, Inc. | 3 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$211
How this compares
$2,918 in reported general payments places this provider in the 75th percentile of 1,490 medical providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 34 | $43,599 |
| OzempicSemaglutide | 18 | $29,736 |
| TradjentaLinagliptin | 19 | $23,131 |
| Atorvastatin Calcium | 152 | $829 |
| Gabapentin | 32 | $517 |
| Rosuvastatin Calcium | 32 | $435 |
| Lisinopril | 68 | $363 |
| Tamsulosin Hcl | 33 | $335 |
| Metformin Hcl | 66 | $299 |
| Levothyroxine Sodium | 43 | $271 |
| Alendronate Sodium | 40 | $270 |
| Amlodipine Besylate | 70 | $256 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 14 | $247 |
| Omeprazole | 23 | $221 |
| Montelukast Sodium | 33 | $192 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $502 | $43,59934 claims |
| Novo NordiskOzempic | $512 | $29,73618 claims |
| Boehringer IngelheimTradjenta | $283 | $23,13119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,490 medical providers in Texas.
Other medical in Dallas
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Danny DeckardDallas$101K
- Janine ShinnDallas$84K
- Andrew GarzaDallas$43K
- Alyssa SpiegelDallas$18K
- Jose de la CerdaSan Antonio$1.1M
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.